NASH

Explore the complexities of NASH research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against NASH with flcube.com.

SynRx Therapeutics' SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status
CompanyDrug

SynRx Therapeutics’ SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status

SynRx Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to SYN818, the company's proprietary Polθ (DNA polymerase theta) inhibitor, in combination with…

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline
CompanyDrug

Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline

Novo Nordisk to Acquire Akero Therapeutics for $5.2 Billion, Secures Future Value with Efruxifermin
CompanyDeals

Novo Nordisk to Acquire Akero Therapeutics for $5.2 Billion, Secures Future Value with Efruxifermin

Hengrui’s HRS‑4729 GLP‑1 Triple Agonist Receives NMPA Approval for MASLD & MASH
CompanyDrug

Hengrui’s HRS‑4729 GLP‑1 Triple Agonist Receives NMPA Approval for MASLD & MASH

Novo Nordisk's Wegovy Granted FDA Approval for Metabolic-Associated Steatohepatitis
CompanyDrug

Novo Nordisk’s Wegovy Granted FDA Approval for Metabolic-Associated Steatohepatitis

Boehringer Ingelheim and Echosens Expand Partnership to Tackle MASH
CompanyDeals

Boehringer Ingelheim and Echosens Expand Partnership to Tackle MASH

Suzhou's PegBio Launches Hong Kong IPO Amid Pipeline Progress
CompanyDeals

Suzhou’s PegBio Launches Hong Kong IPO Amid Pipeline Progress

Eli Lilly Licenses OliX Pharma's OLX75016 for MASH and Cardiometabolic Diseases
CompanyDeals

Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases

Huadong Medicine's DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials
CompanyDrug

Huadong Medicine’s DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials

Show More